Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic
- PMID: 37065774
- PMCID: PMC10052936
- DOI: 10.1016/j.dadr.2023.100155
Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic
Abstract
Background: The pandemic has changed many aspects of healthcare, including the treatment of people with opioid use disorder with buprenorphine. Prior to the pandemic, rural health disparities existed in the accessibility of this treatment. Rural and frontier areas of the United States, particularly the Great Plains, had few or no providers of this evidence-based treatment. This study aimed to investigate how access to buprenorphine changed in the Great Plains during the pandemic.
Methods: This retrospective observational study compared the number of weekly patient appointments resulting in a buprenorphine prescription for 55 weeks before the start of the SARS-CoV-2 pandemic and 55 weeks after. Electronic health records of the largest rural health provider in the Great Plains were queried. Patients were categorized as coming from a frontier location or a non-frontier location based on the home address provided at the visit. The USDA defines frontier as communities that are small and distant from urban centers. Time series analysis was utilized to understand changes in weekly visits during this period.
Results: A significant increase in weekly buprenorphine visits occurred after the pandemic's start. Further, females and people from frontier locations had significantly higher numbers of buprenorphine visits.
Conclusions: In an area of the country with low pre-existing access to buprenorphine treatment for opioid use disorder, increases in buprenorphine visits were found after the pandemic began. This was particularly true of females who reside in frontier areas. Pandemic-related changes may have reduced barriers to this critical treatment, especially among rural populations.
Keywords: Buprenorphine; Opioid use disorder; Pandemic; Rural health disparities.
© 2023 The Author. Published by Elsevier B.V.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures

Similar articles
-
Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky.J Rural Health. 2023 Jan;39(1):186-196. doi: 10.1111/jrh.12669. Epub 2022 May 24. J Rural Health. 2023. PMID: 35610181 Free PMC article.
-
Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.Cureus. 2021 Nov 24;13(11):e19870. doi: 10.7759/cureus.19870. eCollection 2021 Nov. Cureus. 2021. PMID: 34976492 Free PMC article. Review.
-
Barriers to accessing opioid agonist therapy in pregnancy.Am J Obstet Gynecol MFM. 2020 Nov;2(4):100225. doi: 10.1016/j.ajogmf.2020.100225. Epub 2020 Sep 15. Am J Obstet Gynecol MFM. 2020. PMID: 33345932
-
Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.JAMA Netw Open. 2021 Apr 1;4(4):e216147. doi: 10.1001/jamanetworkopen.2021.6147. JAMA Netw Open. 2021. PMID: 33856474 Free PMC article.
-
An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.J Rural Health. 2021 Jun;37(3):467-472. doi: 10.1111/jrh.12570. Epub 2021 Mar 15. J Rural Health. 2021. PMID: 33720447 Free PMC article.
Cited by
-
Changes in Substance Use Diagnoses in the Great Plains during the COVID-19 Pandemic.Healthcare (Basel). 2024 Aug 16;12(16):1630. doi: 10.3390/healthcare12161630. Healthcare (Basel). 2024. PMID: 39201189 Free PMC article.
References
-
- AHRQ, 2023. The distribution of the U.S. primary care. Accessed on 1.30.23 from: https://www.ahrq.gov/research/findings/factsheets/primary/pcwork3/index.....
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous